Tissue Regenix Group plc

Company Profile

Company website
Sector
Pharmaceuticals & Biotechnology (Biotechnology)
Description

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

Investor Access

30 Sep
Event information

Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 16:00 BST on Tuesday 30 September. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

Venue
online
Time
16:00 BST on Tuesday 30 September
Financial Calendar
 Event  Date
Year End 31 December
Half  Year End 30 June
Preliminary Results* June
Interim Results 30 September
AGM* June

* Months based on previous announcements of this kind